Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29599386 | 1.00 | MTNR1A (0.61) | MTNR1AMTNR1BDRD2DRD4DRD3 | |
| SCHEMBL823055 | 1.00 | MTNR1A (0.61) | MTNR1AMTNR1BDRD2DRD4DRD3 | |
| SCHEMBL823057 | 1.00 | MTNR1A (0.61) | MTNR1AMTNR1BDRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL7430755 | 0.98 | MTNR1A (0.59) | MTNR1AMTNR1BDRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL1026136 | 0.98 | MTNR1A (0.59) | MTNR1AMTNR1BDRD2DRD4DRD3 | |
| SCHEMBL714537 | 0.84 | SIGMAR1 (0.53) | MTNR1AMTNR1BDRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL1027335 | 0.82 | SIGMAR1 (0.52) | MTNR1AMTNR1BDRD2DRD4DRD3 | |
| SCHEMBL7838746 | 0.79 | MTNR1A (0.61) | MTNR1AMTNR1BMAOAMAOBGRIN2B | |
| SCHEMBL459537 | 0.79 | GRIN2B (0.65) | MTNR1AMTNR1BMAOAMAOBGRIN2B | |
| SCHEMBL25909439 | 0.79 | GRIN2B (0.56) | MTNR1AMTNR1BMAOAMAOBGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230321033-A1 | THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS | ENYO PHARMA (FR) | 2023-10-12 | — | — | US | disclosed |
| US-20230107499-A1 | HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2023-04-06 | — | — | US | disclosed |
| CN-115348959-A | Heteroaryl compounds and their therapeutic use in disorders associated with altered beta-glucocerebrosidase activity | 增益治疗股份有限公司 | 2022-11-15 | — | — | CN | disclosed |
| EP-4065563-A1 | HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | Gain Therapeutics SA (CH) | 2022-10-05 | — | — | EP | disclosed |
| EP-2970315-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-09-15 | — | — | EP | disclosed |
| EP-2970308-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| WO-2021105908-A1 | HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | GAIN THERAPEUTICS SA (CH) | 2021-06-03 | — | — | WO | disclosed |
| EP-3189048-B1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-03-17 | — | — | EP | disclosed |
| EP-3189048-B1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY LTD (AU) | 2021-03-17 | — | — | EP | disclosed |
| EP-0817767-A1 | BICYCLIC AMINE DERIVATIVES AND THEIR USE AS ANTI-PSYCHOTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996030333-A1 | BICYCLIC AMINE DERIVATIVES AND THEIR USE AS ANTI-PSYCHOTIC AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1996-10-03 | — | — | WO | disclosed |
| US-5272157-A | Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application | SYNTHELABO (FR) | 1993-12-21 | — | — | US | disclosed |
| US-5179108-A | Antiserotonin agents or cardiovascular disorders | SYNTHELABO (FR) | 1993-01-12 | — | — | US | disclosed |
| WO-1992007821-A1 | DIASTEREOISOMERS OF BICYCLO-SUBSTITUTED PHENYLACETONITRILE DERIVATIVES | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |
| EP-0447292-A1 | 4-Aminomethyl-piperidine derivatives, their preparation and therapeutic application | SYNTHELABO (FR) | 1991-09-18 | — | — | EP | disclosed |
| US-4681970-A | CARDIOVASCULAR AGENTS | G. D. SEARLE & CO. (US) | 1987-07-21 | — | — | US | disclosed |
| US-4593042-A | hypotensive agent | G. D. SEARLE & CO. (US) | 1986-06-03 | — | — | US | disclosed |
| US-4584293-A | LOWER HEART RATE AND OXYGEN REQUIREMENT | DR. KARL THOMAE GMBH (DE) | 1986-04-22 | — | — | US | disclosed |
| EP-0161604-A2 | Aminotetralin derivatives, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107499-A1 | HETEROARYL COMPOUNDS AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE | GBA1, GBA2, GBA3 | MTNR1A 2738/4885MTNR1B 1644/4885DRD2 1316/4885 |
| US-20230321033-A1 | THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS | TST, TPMT, MMP1 | MTNR1A 663/4885MTNR1B 112/4885DRD2 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.